DIACOMIT POWDER FOR SUSPENSION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

STIRIPENTOL

Prieinama:

BIOCODEX SAS

ATC kodas:

N03AX17

INN (Tarptautinis Pavadinimas):

STIRIPENTOL

Dozė:

500MG

Vaisto forma:

POWDER FOR SUSPENSION

Sudėtis:

STIRIPENTOL 500MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/60/90 PCK

Recepto tipas:

Prescription

Gydymo sritis:

MISCELLANEOUS ANTICONVULSANTS

Produkto santrauka:

Active ingredient group (AIG) number: 0153530002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2012-12-21

Prekės savybės

_ _
_ _
_DIACOMIT stiripentol _
_Page 1 of 38 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DIACOMIT™*
stiripentol
Capsules, 250 mg and 500 mg, Oral
Powder for suspension, 250 mg and 500 mg, Oral
In-House Standard
Antiepileptic [N03AX17]
Biocodex SAS
7 Avenue Gallieni
94250 Gentilly
France
Imported/Distributed by:
Biocodex Canada Inc.
320 Harry Walker Parkway North, 14
Newmarket, ON, L3Y 7B4
Date of Initial Authorization:
December 19, 2012
Date of Revision:
July 14, 2021
Submission Control Number: 248895
*All trademark rights used under license
_ _
_ _
_ _
_DIACOMIT stiripentol _
_Page 2 of 38_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
07/2021
RECENT MAJOR LABEL
CHANGES............................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.3
Reconstitution
...................................................................................................
7
4.4
Administration......................................................................